labetalol has been researched along with Substance Withdrawal Syndrome in 11 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 7.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| "6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma." | 5.26 | Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. ( Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 3.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| "1 Forty-one patients with mild to moderate hypertension have been treated with labetalol for up to 5 years." | 3.66 | A long-term study of labetalol in general practice. ( Gregg, I; Kane, J; Stephens, MD, 1979) |
| "6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma." | 1.26 | Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. ( Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sofuoglu, M | 1 |
| Babb, D | 1 |
| Hatsukami, DK | 1 |
| Prichard, BN | 1 |
| Reid, JL | 1 |
| Meredith, PA | 1 |
| Elliott, HL | 1 |
| Rosenthal, T | 1 |
| Rabinowitz, B | 1 |
| Boichis, H | 1 |
| Elazar, E | 1 |
| Brauner, A | 1 |
| Neufeld, HN | 1 |
| Cumming, AM | 1 |
| Brown, JJ | 4 |
| Lever, AF | 4 |
| Robertson, JI | 4 |
| Rosei, EA | 3 |
| Fraser, R | 1 |
| Morton, JJ | 1 |
| Trust, PM | 3 |
| Kane, J | 1 |
| Gregg, I | 1 |
| Stephens, MD | 1 |
| Hurley, DM | 1 |
| Vandongen, R | 1 |
| Beilin, LJ | 1 |
| Robertson, AS | 2 |
| Mehta, JL | 1 |
| Lopez, LM | 1 |
2 reviews available for labetalol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Labetalol and the management of hypertension.
Topics: Adrenal Gland Neoplasms; Clonidine; Ethanolamines; Humans; Hypertension; Labetalol; Pheochromocytoma | 1981 |
1 trial available for labetalol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Female; Ganglionic Sti | 2003 |
8 other studies available for labetalol and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.
Topics: Adult; Blood Pressure; Catecholamines; Clonidine; Cyclic AMP; Ethanolamines; Female; Humans; Hyperte | 1981 |
Intravenous labetalol in the treatment of severe hypertension.
Topics: Adrenal Gland Neoplasms; Catecholamines; Clonidine; Ethanolamines; Humans; Hypertension; Infusions, | 1982 |
Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aldosterone; Angiotensin II; Cloni | 1976 |
A long-term study of labetalol in general practice.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Family Practice; Humans; Hypertension; Labetalol; Long-T | 1979 |
Failure of labetalol to prevent hypertension due to clonidine withdrawal.
Topics: Adult; Clonidine; Drug Combinations; Ethanolamines; Female; Humans; Hypertension; Labetalol; Substan | 1979 |
Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.
Topics: Administration, Oral; Adult; Clonidine; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension | 1976 |
Letter: Emergency treatment of hypertensive crisis following clonidine withdrawal.
Topics: Clonidine; Humans; Hypertension; Labetalol; Pheochromocytoma; Substance Withdrawal Syndrome | 1976 |
Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol.
Topics: Aged; Clonidine; Humans; Hypertension; Labetalol; Male; Metoprolol; Substance Withdrawal Syndrome | 1987 |